U.S. Food and Drug Administration Approves Augtyro™ (Repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (Tki), for the Treatment of Patients With Ntrk-Positive Locally Advanced or Metastatic Solid Tumors
美國食品和藥物管理局批准Augtyro™(Repotrectinib)，一種下一代酪氨酸激酶抑制劑(TKI)，用於治療NTRK陽性局部晚期或轉移性實體腫瘤患者。